

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant(s): Jeffrey W. Strovel

Serial No.:

10/591,049

Art Unit: Unassigned

Filed:

5 May 2008

Examiner: Unassigned

TITLE:

Determining Cancer-Linked Genes and Therapeutic Targets Using

Cytogenetic Methods

Docket No.: 689290-275

30 January 2009

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### **Transmittal**

Sir:

In support of the above-referenced application for patent, Applicant hereby forwards the following:

- 1. Information Disclosure Statement (3 sheets);
- 2. Form 1449 (1 sheet);
- 3. Copy of 3 references;
- 4. Copy of International Search Report; and
- 5. Self-addressed, return post card.

No fee is believed due in filing this paper. The Commissioner is authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

Serial No. 10/591,049 Docket No. 689290-275

### FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

> Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Alan J. Grant , Esq.

Date

Respectfully submitted,

Alan J. Grant, Esq. Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN 5 Becker Farm Road

Roseland, NJ 07068 Phone: 973-994-1700 Fax: 973-994-1744



Applicant(s): Jeffrey W. Strovel

Serial No.: 10/591,049

Art Unit: Unassigned

Filed:

5 May 2008

Examiner: Unassigned

TITLE:

Determining Cancer-Linked Genes and Therapeutic Targets Using

Cytogenetic Methods

Docket No.: 689290-275

30 January 2009

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# INFORMATION DISCLOSURE STATEMENT

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449, which may be material to the patentability of the above-identified application. Applicant(s) make no admission that the cited references are prior art or that these references are in fact material to the patentability of the above-entitled application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

X\_§1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR

Serial No.: 10/591,049 Docket No. 689290-275 Before the mailing of a first Office Action on the merits. (3) No fee or statement is required. §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either: A Final Action or under 37 CFR §1.113; OR (1) A Notice of Allowance under 37 CFR §1.311; AND (2) is accompanied by either: (check one) The statement as specified in 37 CFR §1.97(e) set out below: OR The fee of \$180.00 under 37 CFR §1.17(p). This Information Disclosure Statement is filed after the mailing date §1.97(d) of either: a Final Action or under 37 CFR §1.113; OR (1) A Notice of Allowance under 37 CFR §1.311; (2)BUT filed on or before payment of the Issue Fee; AND is accompanied by: The statement as specified in 37 CFR §1.97(e) as set (1) forth below: AND Petition is hereby made under 37 CFR §1.97(d) for (2) consideration of this Information Disclosure Statement; AND. The petition fee of \$130.00 set out in 37 CFR §1.17(i). (3) §1.97(e) The undersigned Attorney hereby states that: each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement; no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the

undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure

Statement.

Serial No.: 10/591,049 Docket No. 689290-275

The Examiner is respectfully requested to consider and make of record all of the cited documents.

The Commissioner is authorized to charge payment of any additional fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

## FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Alan J. Grant , Esq.

Nata

Respectfully submitted,

Alan J. Grant, Esq. Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN 5 Becker Farm Road

Roseland, NJ 07068 Phone: 973-994-1700

Fax: 973-994-1744